Business Wire

SES

9.11.2022 08:51:41 CET | Business Wire | Press release

Share
SES Selects Arianespace to Launch EAGLE-1 Satellite for Europe’s Quantum Cryptography

The EAGLE-1 satellite, which will support the end-to-end secure Quantum Key Distribution (QKD) system for Europe, will be launched for SES by Arianespace on a Vega C rocket from French Guiana as early as Q4 2024. The satellite will be placed into Low Earth Orbit (LEO). The EAGLE-1 project comprising satellite and ground infrastructure, is developed by SES and its consortium of 20 European partners, with the European Space Agency (ESA) and the European Commission support.

Under the recently-signed agreement with ESA, SES and its partners will design, develop, launch and operate a satellite-based end-to-end QKD system for the purpose of testing and validating space-based secure transmission of cryptographic keys. The first European sovereign space-based QKD system will include the dedicated low earth orbit (LEO) EAGLE-1 satellite and state-of-the-art QKD operations centre in Luxembourg. In the scope of EuroQCI, the EAGLE-1 satellite will enable early access, validation, and integration of space-based QKD for EU Member States.

“Building the EAGLE-1 end-to-end system for secure data transmission and validating the long-distance Quantum Key Distribution technology is an innovative project that will benefit the EU Member States,” said Ruy Pinto, Chief Technology Officer at SES. “We have been working with Arianespace for decades to deliver our satellites into space and are delighted for them to be onboard to launch the EAGLE-1 satellite into orbit.”

“We are delighted and honored by this renewed mark of confidence from the leading global content connectivity service provider SES,” noted Marino Fragnito, Director of Arianespace’s Vega business unit. “Over the last 38 years, Arianespace has carried out 42 launches for its longstanding partner, and Vega C will now continue this successful track record. It is a great honor for us to support our customer’s ambitions and to be part of this mission that aims at implementing Europe’s satellite-enabled cybersecurity technology.”

Following the launch, the EAGLE-1 satellite will complete three years of in-orbit mission supported by the European Commission. During this operational phase, the satellite will allow European Union governments and institutions, as well as critical business sectors, early access to long-distance QKD that would path the way towards an EU constellation enabling ultra-secure data transmissions.

The EAGLE-1 project is co-funded by the ESA contribution of Germany, Luxembourg, Austria, Italy, the Netherlands, Switzerland, Belgium, and the Czech Republic under ARTES, as well as the European Commission through Horizon Europe.

Vega C, the new European light launcher successfully passed its inaugural flight on July 13 and now enters its operational phase under the responsibility of Arianespace. With this contract, Vega C backlog includes over 40 satellites contracts.

Vega C development program has been managed by ESA with 12 Member States of the Agency. Avio Spa (Colleferro, Italy) is the industrial prime of the Vega launch system. Vega C has been upgraded with more powerful first and second stage Solid Rocket Motors and with a larger fairing, which significantly increases payload mass and double allowable volume as compared to Vega. The launcher also better meets the specific needs of small spacecrafts, thanks to its improved SSMS dispenser and to its AVUM+ that allows seven re-ignitions instead of five. Vega C can thus deliver to three different separation orbits for its multiple payloads within the same mission, instead of the two previously possible with Vega.

For more information, visit the EAGLE-1 Newsroom

Follow SES on:

Twitter | Facebook | YouTube | LinkedIn | Instagram

Read our Blogs >

Visit the Media Gallery >

Follow Arianespace on:

Twitter | YouTube | LinkedIn | Instagram

About ESA

The European Space Agency (ESA) is Europe’s gateway to space. ESA is an intergovernmental organisation, created in 1975, with the mission to shape the development of Europe’s space capability and ensure that investment in space delivers benefits to the citizens of Europe and the world. For more information see www.esa.int

The Telecommunications and Integrated Applications Directorate (TIA) supports innovation to boost the competitiveness of European industry in the global space market. This involves a wide range of activities, from space-based technology, systems, products for telecommunications development to the down-to-Earth application of space-based services. It also calls for engagement with a wide range of industrial, academic, and institutional partners. For more information, please visit our website: https://artes.esa.int/

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries ~8,000 channels and has an unparalleled reach of 366 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.

About Arianespace

Arianespace uses Space to make life better on Earth by providing launch services for all types of satellites into all orbits. It has orbited over 1,100 satellites since 1980. Arianespace is responsible for operating the new-generation Ariane 6 and Vega C launchers, developed by ESA, with respectively ArianeGroup and Avio as industrial primes. Arianespace is headquartered in Evry, near Paris, and has a technical facility at the Guiana Space Center in French Guiana, plus local offices in Washington, D.C., Tokyo and Singapore. Arianespace is a subsidiary of ArianeGroup, which holds 74% of its share capital, with the balance held by 15 other shareholders from the Ariane and Vega European launcher industry, and ESA and Cnes as censors.

www.arianespace.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221108006349/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye